Publications
2024
Lindley RA, Hall NE and Mamrot J. (2024) Predicting response of patients with NSCLC to immunotherapy using innate immune fitness (IIF) profiling. J Clin Oncol 42, 2024 (ASCO suppl 16; abstr 8038).
Mamrot J, Lindley RA. & Hall NE. (2024) Deaminase-associated mutation motifs as predictive biomarkers of anti-PD-(L)1 / CTLA-4 therapy response in non-small cell lung cancer. Article in Preparation. (In Preparation)
Steele EJ, Franklin A, Lindley RA. (2024) Somatic Mutation Patterns at Ig and Non-Ig Loci. DNA Repair. 2024 Jan;133:103607. doi: 10.1016/j.dnarep.2023.103607. Epub 2023 Nov 28. PMID: 38056368.
2022
Gorczynski RM, Wickramasinghe NC, Lindley RA, Steele EJ. (2022) Time for fresh constructive scientific debate on the origin of, immune response to, and optimal vaccination strategy for, infection with SARS-CoV-2. J. Clinical Immunology and Infectious Diseases. In Review 17 June 2022.
2021
Mamrot J, Hall E, Lindley RA. (2021) Identification and validation model to identify cancer progression signatures in multiple cancers. Oncotarget, 12(8). https://www.oncotarget.com/article/27934/
2020
Lindley RA. (2020) A Review of the mutational role of deaminases and the generation of a cognate molecular model to explain cancer mutation spectra. Medical Research Archives, 8(8). https://journals.ke-i.org/mra/article/view/2177
Hall NE, Mamrot J, Steele EJ, Frampton C, Read P, Bischoff R, Lindley RA. (2020) Blood and saliva-derived exomes from healthy Caucasian subjects do not display overt evidence of somatic mosaicism. Mut Res Fund Mech Mutagen 821 (2020) 111705
https://doi.org/10.1016/j.mrfmmm.2020.111705
2019
Mamrot J, Balachandran S, Steele EJ, Lindley RA. (2019) Molecular model linking Th2 polarized M2 tumour-associated macrophages with deaminase-mediated cancer progression mutation signatures. Scandinavian Journal of Immunology, 89(5): e12760. doi: 10.1111/sji.12760.
Lindley RA and Steele EJ. (2019) Deaminases and Why Mice Sometimes Lie in Immuno-Oncology Pre-Clinical Trials. Annals of Clinical Oncology. 2(1): pp2-5. doi: 10.31487/j.ACO.2019.01.001.
2018
Lindley RA, Hall NE. (2018) APOBEC and ADAR deaminases may cause many single nucleotide polymorphisms curated in the OMIM database. Mutation Research. 810(1): pp33-38. doi: 10.1016/j.mrfmmm.2018.03.008.
Steele EJ, Lindley RA. (2018) Germline V repertoires: Origin, maintenance, diversification. Scandinavian Journal of Immunology. 87(6): e12670. doi: 10.1111/sji.12670.
2017
Steele EJ and Lindley RA. (2017) ADAR deaminase A-to-I editing of DNA and RNA moieties
of RNA:DNA hybrids has implications for the mechanism of Ig somatic hypermutation. DNA Repair. 55(1): pp1-6. doi: 10.1016/j.dnarep.2017.04.004.
2016
Lindley RA, Humbert P, Larner C, Akmeemana EH, Pendlebury CR. (2016) Association between targeted somatic mutation (TSM) signatures and HGS-OvCa progression. Cancer Medicine. 5(9): pp2629-2640. doi: 10.1002/cam4.825.
2013
Lindley RA. (2013) The importance of codon context for understanding the Ig-like somatic hypermutation strand-biased patterns in TP53 mutations in breast cancer. Cancer Genetics. 206(6): pp222-6. doi: 10.1016/j.cancergen.2013.05.016.
Lindley RA and Steele EJ. (2013) Critical analysis of strand-biased somatic mutation signatures in TP53 versus Ig genes, in genome -wide data and the etiology of cancer. International Scholarly Research Notices: Genetics. Article ID: 921418. doi: 10.1155/2013/921418.
2011
Steele EJ, Lindley RA, Weiller GW. (2011) Somatic hypermutation and the discovery of A-to-I RNA editing sites? Biochemical and Biophysical Research Communications. 414(2): p443. doi: 10.1016/j.bbrc.2011.09.111.
2010
Steele EJ, Lindley RA. (2010) Somatic mutation patterns in non-lymphoid cancers resemble the strand biased somatic hypermutation spectra of antibody genes. DNA Repair. 9(6): pp600-603. doi: 10.1016/j.dnarep.2010.03.007.
2006
Steele EJ, Lindley RA, Wen J, Weiller GF. (2006) Computational analyses show A-to-G mutations correlate with nascent mRNA hairpins at somatic hypermutation hotspots. DNA Repair. 5(11): pp1346-1363. doi: 10.1016/j.dnarep.2006.06.002.